Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281673769> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W4281673769 endingPage "e21158" @default.
- W4281673769 startingPage "e21158" @default.
- W4281673769 abstract "e21158 Background: Brain metastasis (BM) is the first cause of poor prognosis in non-small cell lung cancer (NSCLC) patients. To date, localized whole-brain radiotherapy (WBRT) is still the therapeutic option for patients with extensive BM. However, effectiveness is currently unsatisfactory. This study aimed to investigate the effects of Rh-endostatin combined with WBRT on NSCLC patients with BMs. Methods: 43 NSCLC patients with BMs were divided into two groups randomly. Rh-endostatin combination group (n = 19) received WBRT combined with Rh-endostatin, and radiation group (n = 24) received WBRT alone. The primary endpoint of the study was progression free survival (PFS). The secondary endpoints were intracranial progression free survival (iPFS), overall survival (OS), objective response rate (ORR) and the change of cerebral blood volume (CBV), cerebral blood flow (CBF) of the contrast medium pre- and one month post-radiation. Results: Median progression-free survival (PFS) was 8.1 months in the Rh-endostatin combination group versus 4.9 months in the radiation group (95%CI: 0.2612-0.9583, p= 0·0428). Besides, median iPFS was 11.6 months in Rh-endostatin combination group versus 4.8 months in the radiation group (95%CI：0.2530-0.9504, p= 0·0437). Overall survival (OS) was 14.2 months in the Rh-endostatin combination group versus 6.4 months in the radiation group (95%CI：0.2508-1.026, p= 0·0688). Compared with radiotherapy alone, CBV and CBF in the Rh-endostatin combination group increased more significantly than before radiotherapy, indicating that Rh-endostatin may improve local blood supply and microcirculation. Conclusions: Rh-endostatin showed better survival and a safety profile, improved cerebral perfusion and increased the quality of life of NSCLC patients with BMs. Clinical trial information: NCT03614065." @default.
- W4281673769 created "2022-06-13" @default.
- W4281673769 creator A5027595700 @default.
- W4281673769 creator A5037677450 @default.
- W4281673769 creator A5041915013 @default.
- W4281673769 creator A5046922491 @default.
- W4281673769 creator A5051572429 @default.
- W4281673769 creator A5052025786 @default.
- W4281673769 creator A5070591558 @default.
- W4281673769 creator A5077703494 @default.
- W4281673769 creator A5089520243 @default.
- W4281673769 date "2022-06-01" @default.
- W4281673769 modified "2023-09-26" @default.
- W4281673769 title "Efficacy and safety of recombinant human endostatin combined with whole-brain radiotherapy in patients with brain metastases from NSCLC." @default.
- W4281673769 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e21158" @default.
- W4281673769 hasPublicationYear "2022" @default.
- W4281673769 type Work @default.
- W4281673769 citedByCount "0" @default.
- W4281673769 crossrefType "journal-article" @default.
- W4281673769 hasAuthorship W4281673769A5027595700 @default.
- W4281673769 hasAuthorship W4281673769A5037677450 @default.
- W4281673769 hasAuthorship W4281673769A5041915013 @default.
- W4281673769 hasAuthorship W4281673769A5046922491 @default.
- W4281673769 hasAuthorship W4281673769A5051572429 @default.
- W4281673769 hasAuthorship W4281673769A5052025786 @default.
- W4281673769 hasAuthorship W4281673769A5070591558 @default.
- W4281673769 hasAuthorship W4281673769A5077703494 @default.
- W4281673769 hasAuthorship W4281673769A5089520243 @default.
- W4281673769 hasConcept C121608353 @default.
- W4281673769 hasConcept C126322002 @default.
- W4281673769 hasConcept C141071460 @default.
- W4281673769 hasConcept C143998085 @default.
- W4281673769 hasConcept C168563851 @default.
- W4281673769 hasConcept C203092338 @default.
- W4281673769 hasConcept C2776256026 @default.
- W4281673769 hasConcept C2778164965 @default.
- W4281673769 hasConcept C2779013556 @default.
- W4281673769 hasConcept C2780394083 @default.
- W4281673769 hasConcept C2780739268 @default.
- W4281673769 hasConcept C3019894029 @default.
- W4281673769 hasConcept C509974204 @default.
- W4281673769 hasConcept C71924100 @default.
- W4281673769 hasConcept C75920679 @default.
- W4281673769 hasConceptScore W4281673769C121608353 @default.
- W4281673769 hasConceptScore W4281673769C126322002 @default.
- W4281673769 hasConceptScore W4281673769C141071460 @default.
- W4281673769 hasConceptScore W4281673769C143998085 @default.
- W4281673769 hasConceptScore W4281673769C168563851 @default.
- W4281673769 hasConceptScore W4281673769C203092338 @default.
- W4281673769 hasConceptScore W4281673769C2776256026 @default.
- W4281673769 hasConceptScore W4281673769C2778164965 @default.
- W4281673769 hasConceptScore W4281673769C2779013556 @default.
- W4281673769 hasConceptScore W4281673769C2780394083 @default.
- W4281673769 hasConceptScore W4281673769C2780739268 @default.
- W4281673769 hasConceptScore W4281673769C3019894029 @default.
- W4281673769 hasConceptScore W4281673769C509974204 @default.
- W4281673769 hasConceptScore W4281673769C71924100 @default.
- W4281673769 hasConceptScore W4281673769C75920679 @default.
- W4281673769 hasIssue "16_suppl" @default.
- W4281673769 hasLocation W42816737691 @default.
- W4281673769 hasOpenAccess W4281673769 @default.
- W4281673769 hasPrimaryLocation W42816737691 @default.
- W4281673769 hasRelatedWork W2357126231 @default.
- W4281673769 hasRelatedWork W2369094418 @default.
- W4281673769 hasRelatedWork W2376744051 @default.
- W4281673769 hasRelatedWork W2380658010 @default.
- W4281673769 hasRelatedWork W2516942920 @default.
- W4281673769 hasRelatedWork W2799453846 @default.
- W4281673769 hasRelatedWork W2902679640 @default.
- W4281673769 hasRelatedWork W2995717006 @default.
- W4281673769 hasRelatedWork W4281673769 @default.
- W4281673769 hasRelatedWork W4306253774 @default.
- W4281673769 hasVolume "40" @default.
- W4281673769 isParatext "false" @default.
- W4281673769 isRetracted "false" @default.
- W4281673769 workType "article" @default.